Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Refractory Plasma Cell Myeloma: early-phase trial registry
4 of 26 indexed Refractory Plasma Cell Myeloma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #627 of 28,707 conditions by registered trial count.
26 US clinical trials · 4 currently recruiting · #627 of 28,707 conditions by registered trial count
Refractory Plasma Cell Myeloma: 26 US clinical trials tracked, 4 recruiting.
Refractory Plasma Cell Myeloma is the subject of 26 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 25 in Phase 1-2 (earlier-stage). The most active sponsor is Fred Hutchinson Cancer Center, running 5 of these trials.
Enrollment posture brief
Registry condition refractory-plasma-cell-myeloma
OPEN 4 | RECR 15% | LATE 0 | EARLY 25 | RANK #627 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Arthroplasty, Replacement, Knee (15% recruiting · 13 trials)
Refractory Plasma Cell Myeloma lists 4 open slots (15% of 26 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Refractory Plasma Cell Myeloma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Refractory Plasma Cell Myeloma is recruiting below its size-band peers.
4 of 26 indexed trials (15.4%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Refractory Plasma Cell Myeloma research.
Fred Hutchinson Cancer Center accounts for 5 of 26 trials (19.2%). 12 distinct sponsors appear on at least one study for this condition label.
-
Most Refractory Plasma Cell Myeloma trials plan to enrol fewer than 100 people.
Median target enrolment is 30 among the 26 trials that report a genuine target (sentinel values excluded). 23 of those (88.5%) plan for fewer than 100 participants.
-
Refractory Plasma Cell Myeloma research is mostly interventional.
26 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
26 total, page 1 of 1
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
Roswell Park Cancer Institute
NCT05312255
CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma
City of Hope Medical Center
NCT03710421
Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
City of Hope Medical Center
NCT04508790
Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma
City of Hope Medical Center
NCT05363111
Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma
Academic and Community Cancer Research United
NCT04756401
Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
M.D. Anderson Cancer Center
NCT03763162
Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma
Mayo Clinic
NCT04640779
Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial
University of Southern California
NCT05514990
Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma
Emory University
NCT05391750
Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma
Mayo Clinic
NCT05411497
Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma
OHSU Knight Cancer Institute
NCT04850599
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Fred Hutchinson Cancer Center
NCT00105001
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
SWOG Cancer Research Network
NCT01903811
Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement
Emory University
NCT02765854
Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma
M.D. Anderson Cancer Center
NCT01301807
Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma
National Cancer Institute (NCI)
NCT01330173
Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma
Mayo Clinic
NCT01842308
Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma
Fred Hutchinson Cancer Center
NCT00445692
Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
City of Hope Medical Center
NCT02119468
Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma
Fred Hutchinson Cancer Center
NCT00793572
Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma
Fred Hutchinson Cancer Center
NCT03338972
Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma
Albert Einstein College of Medicine
NCT01605032
Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma
City of Hope Medical Center
NCT01163357
90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma
Fred Hutchinson Cancer Center
NCT01503242
Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)
NCT01533194
Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma
Mayo Clinic
NCT03202628
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 14 |
| Phase 2 | 11 |
Top Sponsors
Named interventions
Most-linked intervention names on Refractory Plasma Cell Myeloma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Refractory Plasma Cell Myeloma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Refractory Plasma Cell Myeloma page
26 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Refractory Plasma Cell Myeloma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Fred Hutchinson Cancer Center sponsors the most Refractory Plasma Cell Myeloma trials on record, review their full trial history before evaluating a specific study. See Fred Hutchinson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Refractory Plasma Cell Myeloma condition card totals 26 registered trials; most-linked intervention Dexamethasone; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.